MedTrace Logo

Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

NCT01563926 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2017-02-27

No results posted yet for this study

Summary

This trial is conducted in Asia. The aim of this trial is to evaluate the new liquid somatropin formulation in children with growth hormone deficiency.

Conditions

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children
  • Genetic Disorder
  • Turner Syndrome

Interventions

DRUG

somatropin

Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-23
Primary Completion
2002-10-10
Completion
2002-10-10

Countries

  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01563926 on ClinicalTrials.gov